aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Nimbus Therapeutics, founded as Nimbus Discovery, is a clinical-stage biotechnology company focused on developing breakthrough medicines for metabolic diseases, oncology, and immune-inflammatory disorders. The company's core mission is to harness cutting-edge technologies to design highly selective small molecule therapeutics. Nimbus aims to address significant unmet medical needs through its innovative drug discovery and development processes.
Notable figures associated with Nimbus Therapeutics include its leadership team and board of directors, who bring extensive experience in biotechnology and pharmaceuticals. The company has attracted investments from prominent venture capital firms. Key achievements include advancing multiple programs into clinical trials and forming strategic partnerships to enhance their drug development capabilities. Nimbus Therapeutics has made a significant impact by progressing potential treatments for serious conditions, demonstrating its commitment to improving patient outcomes.
Operating Status
Active
Ownership Type(s)
Public
Main Product(s)
Therapeutics, Drugs
Technology
Biotech
Tags
Healthtech
Model Types
Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
United States
When was Nimbus Therapeutics founded?
Nimbus Therapeutics was founded in 2009.
Where is Nimbus Therapeutics's headquarters located?
Nimbus Therapeutics's headquarters is located in Cambridge, MA, US.
When was Nimbus Therapeutics's last funding round?
Nimbus Therapeutics's most recent funding round was for $210M (USD) in September 2023.
How many employees does Nimbus Therapeutics have?
Nimbus Therapeutics has 112 employees as of Feb 4, 2024.
How much has Nimbus Therapeutics raised to-date?
As of July 05, 2023, Nimbus Therapeutics has raised a total of $637M (USD) since Sep 6, 2023.
Add Comparison
Total Raised to Date
$637M
USD
Last Update Sep 6, 2023
Last Deal Details
$210M
USD
Sep 6, 2023
Private Equity
Total Employees Over Time
112
As of Feb 2024
Nimbus Therapeutics Address
25 First Street
Suite 404
Cambridge,
Massachusetts
02141
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts